Patricia M. Sheean

Patricia M. Sheean

Auto-generated profile, based on publicly available information

Patricia M. Sheean

Institute for Health Research & Policy, University of Illinois at Chicago

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2013 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
PSPatricia M. Sheean
Patricia M. Sheean
SPSarah J. Peterson
Sarah J. Peterson
SPSandra Gomez Perez
Sandra Gomez Perez
KTKaren Troy
Karen Troy
APAnkur Patel
Ankur Patel
CBCarol A. Braunschweig
Carol A. Braunschweig

19 August 2012 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
PSPatricia M. Sheean
Patricia M. Sheean
KHKent Hoskins
Kent Hoskins
MSMelinda Stolley
Melinda Stolley

1 October 2013 in Clinical Nutrition
Verified
Journal Article
Closed access
PSPatricia M. Sheean
Patricia M. Sheean
SPSarah J. Peterson
Sarah J. Peterson
YCYimin Chen
Yimin Chen
DLDishan Liu
Dishan Liu
OLOmar Lateef
Omar Lateef
CBCarol A. Braunschweig
Carol A. Braunschweig

1 September 2004 in Journal of the American Dietetic Association
Verified
Journal Article
Closed access
PSPatricia M. Sheean
Patricia M. Sheean
CBCarol Braunschweig
Carol Braunschweig
ERElizabeth Rich
Elizabeth Rich

14 May 2012 in Journal of the Academy of Nutrition and Dietetics
Verified
Journal Article
Closed access
PDF file
PSPatricia M. Sheean
Patricia M. Sheean
SPSarah J. Peterson
Sarah J. Peterson
WZWeihan Zhao
Weihan Zhao
DGDavid P. Gurka
David P. Gurka
CBCarol A. Braunschweig
Carol A. Braunschweig

18 February 2013 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
PSP M Sheean
P M Sheean
JKJ M Kilkus
J M Kilkus
DLD Liu
D Liu
JMJ Maciejewski
J Maciejewski
CBC A Braunschweig
C A Braunschweig
Parenteral nutrition (PN) exacerbates hyperglycemia, which is associated with increased morbidity and mortality in various cancer populations. By using a retrospective design, we examined incident hyperglycemia in PN and non-PN recipients and the associations with clinical events and 5-year survival in a cohort treated for myeloma with melphalan and auto-SCT (n=112). Clinical comparisons were made at admission, and ‘before’ and ‘after’ initiating PN to discern differences and temporality. Actual infusion times were used for PN patients; time frames based on mean PN infusion days were created for the non-PN recipients. Oral intake was lower ‘before’ in PN vs non-PN patients (P<0.001); however, no differences in mucositis, emesis, infections or transfusions were detected ‘before.’ Incident hyperglycemia (7.0 mmol/L) was significant ‘after’ PN initiation, and PN recipients experienced delays in WBC (P<0.05) and platelet engraftment (P=0.009), and required significantly greater RBC (P=0.0014) and platelet (P=0.001) support ‘after’ than non-PN patients. Neutropenic fever and longer hospital stay were more frequent among PN vs non-PN recipients (P<0.001). Differences in 5-year mortality were not apparent. The findings fail to support clinical benefits of PN administration during auto-SCT for myeloma. Further study is needed to discern if hyperglycemia or feeding per se was deleterious in this patient population.